Summary
Alnylam Pharmaceuticals, Inc. filed an 8-K on May 8, 2014, to report its financial results for the first quarter ended March 31, 2014. The key information provided in this filing is the announcement of these quarterly results via a press release, which is furnished as an exhibit. This 8-K serves as the official notification to investors about the company's performance during the specified period. While the 8-K itself doesn't contain the detailed financial figures, it directs investors to the accompanying press release for that information.
Key Highlights
- 1Alnylam Pharmaceuticals announced its financial results for the quarter ended March 31, 2014.
- 2The announcement was made via a press release issued on May 8, 2014.
- 3The press release containing the detailed financial results is furnished as Exhibit 99.1 to the 8-K filing.
- 4The filing is a standard 8-K reporting event related to the disclosure of material financial information.
- 5Information furnished under Item 2.02 is not considered 'filed' for the purposes of Section 18 of the Exchange Act, limiting liability.
- 6The report confirms Alnylam's principal executive offices are located in Cambridge, MA.
Frequently Asked Questions
The primary purpose of this 8-K filing is to publicly announce Alnylam Pharmaceuticals' financial results for the first quarter of 2014. It serves as notification to investors and the market about the company's performance during that period.
The detailed financial results are contained within the press release dated May 8, 2014, which is provided as Exhibit 99.1 to this 8-K filing. Investors should refer to this exhibit for specific revenue, expense, and other financial data.
This specific 8-K filing primarily reports on past financial results. While the accompanying press release (Exhibit 99.1) might contain forward-looking statements as is common in earnings announcements, the 8-K document itself is focused on the disclosure of the financial results for the quarter ended March 31, 2014.